Lv1
50 积分 2024-09-18 加入
Targeting EZH2 for cancer therapy: From current progress to novel strategies
17天前
已完结
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
17天前
已完结
Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
1个月前
已关闭
Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus
1个月前
已完结
The 2024 APLAR Consensus on the Management of Lupus Nephritis
1个月前
已完结
BTK inhibitors: past, present, and future
2个月前
已完结
Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma
3个月前
已完结
Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects
4个月前
已完结
A Woman with Pancreatitis and Hypertriglyceridemia
5个月前
已关闭
Excipients in medicinal products used in gastroenterology as a possible cause of side effects
5个月前
已完结
皖公网安备34019202002308
